Find activities

220 results

  • Public consultation | Sharing more information about medical devices

    We want your feedback on our proposal to improve sharing information about the safety, quality and performance of medical devices. This will take about 15 minutes to read and complete. The proposed changes intend to provide more information to the public after post-market reviews or investigations of medical devices, particularly where review findings relate to the safety, quality, performance or use of a medical device. These changes align with the intent of An Action Plan... More
    Opened 13 August 2026

  • ODC Medicinal Cannabis Permit Holder Supply Pathways 2026

    The Office of Drug Control (ODC) is seeking feedback from permit holders under the Narcotic Drugs Act 1967 on supply pathways used by industry participants. Your feedback will help the ODC better understand current industry practices and identify opportunities to develop practical guidance and support for licence holders. More
    Closed 16 August 2026

  • Additional public consultation on the scheduling of ethylene oxide, propylene oxide and epichlorohydrin

    Proposed scheduling amendments for ethylene oxide, propylene oxide and epichlorohydrin This consultation is in relation to a proposal to amend the current scheduling of ethylene oxide, propylene oxide and epichlorohydrin. All the three substances are listed is the current Poisons Standard as Dangerous Poisons (Schedule 7) without any exception. The applicant proposed that preparations containing less than 0.002% (20 ppm) of ethylene oxide, propylene oxide and... More
    Opened 17 August 2026

  • Proposed changes to support automated decision making (ADM) for applications to change listed medicines

    Proposed changes to support automated decision making (ADM) for applications to change listed medicines Medicines listed in the Australian Register of Therapeutic Goods (ARTG) under section 26A of the Therapeutic Goods Act 1989 (the Act) are included in the ARTG without pre-market assessment by the Therapeutic Goods Administration (TGA). These medicines are self-listed by the applicant (who becomes the sponsor), or an authorised representative on behalf of a sponsor (such as a... More
    Opened 18 August 2026

  • Radiopharmaceutical regulation in Australia - Open public consultation

    The Therapeutic Goods Administration (TGA) is seeking high‑level stakeholder feedback on how current regulatory settings for radiopharmaceuticals operate in practice. This consultation is intended to support informed consideration of stakeholder experiences with existing regulatory pathways, exemptions and access mechanisms. Feedback received will be used to inform future targeted consultation and engagement activities. To support stakeholder feedback, the TGA has... More
    Closed 21 August 2026

  • Improvements to the Therapeutic Goods Advertising Code

    The Therapeutic Goods Administration (TGA) within the Department of Health, Disability and Ageing is seeking feedback on options and proposed changes to improve the Therapeutic Goods (Therapeutic Goods Advertising Code) Instrument 2021 (the Code). We are reviewing parts of the Code to make sure it: is clear and easy to apply reflects current advertising practices supports safe and appropriate use of therapeutic goods. ... More
    Closed 3 September 2026

  • Proposed changes to Required Advisory Statements for Medicine Labels (RASML)

    The Therapeutic Goods Administration (TGA) is seeking comments from interested parties on proposed changes to the Required Advisory Statements for Medicine Labels (RASML) . RASML sets out advisory statements that are required to be included on the labels of specified OTC and registered complementary medicines. The proposed changes to RASML are: addition of entries for three new substances not currently included in RASML - celecoxib, methenamine and naratriptan ... More
    Closed 4 September 2026

  • Public consultation on proposed amendments to the Poisons Standard in relation to nitrous oxide – Joint ACMS-ACCS #45 – November 2026

    This consultation is for two proposals to amend the current scheduling of nitrous oxide to manage the increasing public health risks from its misuse. The first proposal is initiated by the Delegate and the second proposal has been submitted by a private applicant. Currently, nitrous oxide for therapeutic use is a Prescription only (Schedule 4) substance while for all other uses it a Poison (Schedule 6). Products classified as Schedule 6 are required to carry first aid... More
    Opened today

  • Public consultation on proposed amendments to the Poisons Standard in relation to 4-methylbenzylidene camphor (4-MBC) – Joint ACMS-ACCS #45, November 2026

    This consultation is for a proposal to amend the Poisons Standard in relation to 4-methylbenzylidene camphor (4-MBC). The Delegate and two private applicants have proposed 3 different options to schedule 4-MBC which is not listed in the current Poisons Standard. Option 1 (proposed by the Delegate) This option treats all products consistently and provides one consistent upper limit for 4-MBC for exempting cosmetics and therapeutic sunscreens from the Poisons Standard. ... More
    Opened today

  • Public consultation on proposed amendments to the Poisons Standard – ACCS #43 – NOVEMBER 2026

    Scheduling amendments referred to the Advisory Committee on Chemicals Scheduling This consultation is for Delegate initiated proposals to amend the Poisons Standard. The scheduling amendments and any submissions received will be considered at the November 2026 meeting of the Advisory Committee on Chemicals Scheduling (ACCS) . The closing date for this consultation is close of business 12 OCTOBER 2026. All submissions received by the deadline will be... More
    Opened today
220 results. Page 8 of 8